Tag: breast cancer

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

Data from the dose escalation portion of the Phase 1/2 study of JK06 in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, is being presented at the European Society for Medical Oncology (ESMO) Congress, being held October 17 - 21, 2025, in Berlin, Germany.[1]

In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously “undruggable” cancer-driving protein.

The combination of sacituzumab govitecan (Trodelvy®; Gilead Sciences; See ADC Drugmap)* + pembrolizumab (Keytruda®; Merck & Co/MSD) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care (SoC) pembrolizumab plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC).

Disitamab Vedotin Gains Approval in China for its Third Indication

Now positive topline results from a new study, the DESTINY-Breast11 phase 3 trial (NCT05113251), confirmed that trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca)**, followed by paclitaxel, trastuzumab and pertuzumab (THP), demonstrated a statistically significant and clinically meaningful improvement in pCR rate versus Standard-of-Care (SoC; dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting in patients with high-risk, locally advanced HER2-positive early-stage breast cancer.

The U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to emiltatug ledadotin (XMT-1660; see ADC Drugmap), an antibody-drug conjugate (ADC) targeting B7-H4 (VTCN1), an immune-suppressive plasma membrane protein that is overexpressed in multiple tumor types, including in breast, ovarian, and endometrial cancers, with relatively little or no expression in normal, or healthy, tissues.

In 2022, with an estimated 2.3 million new cases and nearly 700.000 deaths globally, breast cancer emerged as the most prevalent cancer after lung...

The current study results presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) confirm the encouraging efficacy seen in previously treated patients with metastatic and locally advanced breast cancer subtypes, particularly in earlier lines of therapy. The safety and tolerability of Izalontamab Brengitecan are consistent with previously published data.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα / FOLR1)...